Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has
undergone rapid changes with innovations in oncogene-directed therapy and immune …

Targeted therapies are efficient in the context of oncogenic driver mutations. Epidermal
growth factor receptor (EGFR)-mutant lung cancers represent a distinct subset of non-small …

Background The efficacy of immune checkpoint inhibitors (ICIs) in pretreated EGFR-mutated
non-small cell lung cancer (NSCLC) patients is controversial. We conducted this multicenter …

Abstract Objective Immune checkpoint inhibitors (ICIs) have been validated in epidermal
growth factor receptor (EGFR) wild-type advanced non-small cell lung cancer (NSCLC) …

Background Since their first introduction in clinical practice, immune checkpoint inhibitors
showed limited benefit in patients with NSCLC harboring EGFR mutations. With the rationale …

Background: Epidermal growth factor receptor (EGFR) mutations are common in patients
with non-small-cell lung cancer (NSCLC), particularly in Asian populations. Tyrosine kinase …

Background Non‐small cell lung cancer (NSCLC) patients harboring epidermal growth
factor receptor (EGFR)‐mutated who progressed on EGFR tyrosine‐kinase inhibitor (EGFR …

Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase
inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell …

Over the past few years, immune checkpoint inhibitors (ICIs) have greatly improved the
survival for patients with non‐small cell lung cancer (NSCLC) without driver mutations …

Epidermal growth factor receptor (EGFR) mutations occur in 15% of lung adenocarcinomas
in the Caucasian population. A higher incidence is observed in never/light smokers and …